Skip to content
Tech News
← Back to articles

Cognito Therapeutics' light-and-sound headset fails Alzheimer's trial

read original more articles
GoKawiil Brief

Cognito Therapeutics reported that its Spectris AD device, goggles and headphones worn an hour daily to stimulate gamma brain waves, did not slow cognitive decline in a 673-person trial compared with a sham device. Users of the active device scored nearly 9 points worse on a 156-point cognition and function scale after a year. The company still plans to seek FDA approval next year, citing a subgroup of patients with mild cognitive impairment who appeared to benefit.

Why It Matters

GoKawiil's interpretation of the reporting above, not reported fact.

Independent researchers, including Washington University's Eric McDade, called the overall trial result negative and questioned whether a subgroup finding justifies regulatory filing without further study. The outcome could dampen enthusiasm for non-drug, device-based approaches to Alzheimer's treatment, which have drawn attention as alternatives to costly antibody therapies. Whether the FDA accepts subgroup data as sufficient for approval remains uncertain and could set a precedent for similar device trials.

Key Takeaways

Source: nature.com — Mullard, 2026-11-17

Published there as: “‘Light and sound’ therapy for Alzheimer’s flops in long-anticipated trial”

Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.
Keep reading
alzheimer's disease 20 briefs → clinical trial 12 briefs →